Fampyra Detailed description,.

FAMPYRA® (prolonged-release fampridine tablets) is a treatment indicated to improve walking in adult patients with multiple sclerosis (MS) who have walking disability. Biogen Idec has a license from Acorda Therapeutics, Inc to develop and commercialize FAMPYRA in all markets outside the United States. In the U.S this prolonged-release fampridine tablet formulation was developed and is being commercialized by Acorda under the name AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in MS with demonstrated efficacy in adults with MS. FAMPYRA can be used alone or in combination with disease modifying therapies, including immunomodulatory drugs.

 http://www.biogenidec.com/therapies_fampyra.aspx?ID=9793

Canada

Biogen Idec Canada Inc
90 Burnhamthorpe Road West
Suite 1100
Mississauga, Ontario L5B 3C3
Canada
Phone: +1 905 804 1444
Fax: +1 905 897 3222

Global Presence

Biogen Idec is a global organization. In addition to our headquarters in Weston, Massachusetts, we have offices in Argentina, Australia, Brazil, Canada, Japan, China, India and throughout Europe. We operate in 30 countries with distribution partners in over 70.

Countries outside Switzerland may have regulatory requirements or medical practices which are different than those in the Switzerland and may have references to different or additional information. Therefore, the information contained in the sites you are about to enter may not be appropriate for use within Switzerland.

Corporate Headquarters

Biogen Idec Inc
133 Boston Post Road
Weston, MA 02493
USA
Phone: +1 781-464-2000
Fax: +1 617 679 2617
www.biogenidec.com